APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy
Ian D Schnadig, Richy Agajanian, Christopher Dakhil, Nashat Y Gabrail, Robert E Smith Jr, Charles Taylor, Sharon T Wilks, Lee S Schwartzberg, William Cooper, Michael C Mosier, J Yvette Payne, Michael J Klepper, Jeffrey L Vacirca, Ian D Schnadig, Richy Agajanian, Christopher Dakhil, Nashat Y Gabrail, Robert E Smith Jr, Charles Taylor, Sharon T Wilks, Lee S Schwartzberg, William Cooper, Michael C Mosier, J Yvette Payne, Michael J Klepper, Jeffrey L Vacirca
Abstract
Aim: APF530, extended-release granisetron, provides sustained release for ≥5 days for acute- and delayed-phase chemotherapy-induced nausea and vomiting (CINV). We compared efficacy and safety of APF530 versus ondansetron for delayed CINV after highly emetogenic chemotherapy (HEC), following a guideline-recommended three-drug regimen.
Methods: HEC patients received APF530 500 mg subcutaneously or ondansetron 0.15 mg/kg intravenously, with dexamethasone and fosaprepitant. Primary end point was delayed-phase complete response (no emesis or rescue medication).
Results: A higher percentage of APF530 versus ondansetron patients had delayed-phase complete response (p = 0.014). APF530 was generally well tolerated; treatment-emergent adverse event incidence was similar across arms, mostly mild-to-moderate injection-site reactions.
Conclusion: APF530 versus the standard three-drug regimen provided superior control of delayed-phase CINV following HEC. ClinicalTrials.gov : NCT02106494.
Keywords: chemotherapy-induced nausea and vomiting (CINV); extended-release granisetron; highly emetogenic chemotherapy (HEC).
Source: PubMed